InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,332.00
(
0.63%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.49
(
-0.26%
)
Bitcoin
60,880.94
(
0.00%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120317
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 104041

Sunday, 10/31/2010 10:35:49 PM

Sunday, October 31, 2010 10:35:49 PM

Post# of 252939
MRK reports that 44% and 46% of patients in the Boceprevir SPRINT-2 and RESPOND-2 studies, respectively, stopped treatment early according to the response-guided protocol in these studies:

http://finance.yahoo.com/news/Mercks-Investigational-bw-1755524465.html?x=0&.v=1

Early response-guided stopping occurred after 28 weeks in the SPRINT-2 study in the first-line setting (which included a 4-week lead-in period on SoC only) and after 36 weeks in the RESPOND-2 study in the second-line (for non-null-responders in the first line).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up